Biogen acquires three new drugs

Share this article:
Embattled Tysabri maker Biogen Idec announced an agreement yesterday with biopharmaceutical company Protein Design Labs to purchase a multiple sclerosis drug and two other experimental products for approximately $800 million.
As part of the deal, Biogen will initially pay Protein Design $40 million and purchase $100 million of stock from the Fremont, Calif. company.
The agreement covers Protein Design's experimental multiple sclerosis drug daclizumab, which is in Phase II trials. Biogen will also gain rights to a cancer treatment called volociximab, being tested in patients with skin, kidney and pancreatic cancers, and a third drug, Huzaf, being studied in the treatment of Crohn's disease.
Biogen Idec is continuing with a review of its own multiple sclerosis drug Tysabri. The drug was voluntarily removed from the market in March after being linked to deaths from progressive multifocal leukoencephalopathy, a rare neurological disease most often found in patients with compromised immune systems.
Biogen Idec and Elan told MM&M earlier this year it expects to issue a decision on Tysabri in the second half of 2005.
Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...